Ophthalmology and Therapy (Sep 2020)
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
- Asim V. Farooq,
- Simona Degli Esposti,
- Rakesh Popat,
- Praneetha Thulasi,
- Sagar Lonial,
- Ajay K. Nooka,
- Andrzej Jakubowiak,
- Douglas Sborov,
- Brian E. Zaugg,
- Ashraf Z. Badros,
- Bennie H. Jeng,
- Natalie S. Callander,
- Joanna Opalinska,
- January Baron,
- Trisha Piontek,
- Julie Byrne,
- Ira Gupta,
- Kathryn Colby
Affiliations
- Asim V. Farooq
- University of Chicago Medical Center
- Simona Degli Esposti
- NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, UCL Institute of Ophthalmology
- Rakesh Popat
- University College London Hospitals, NHS Foundation Trust
- Praneetha Thulasi
- Emory Eye Center, Emory University
- Sagar Lonial
- Emory University, Winship Cancer Institute
- Ajay K. Nooka
- Emory University, Winship Cancer Institute
- Andrzej Jakubowiak
- University of Chicago Medical Center
- Douglas Sborov
- Huntsman Cancer Institute, University of Utah
- Brian E. Zaugg
- Moran Eye Center, University of Utah
- Ashraf Z. Badros
- University of Maryland School of Medicine
- Bennie H. Jeng
- Department of Ophthalmology and Visual Sciences, University of Maryland School of Medicine
- Natalie S. Callander
- University of Wisconsin, Carbone Cancer Center
- Joanna Opalinska
- GlaxoSmithKline
- January Baron
- GlaxoSmithKline
- Trisha Piontek
- GlaxoSmithKline
- Julie Byrne
- GlaxoSmithKline
- Ira Gupta
- GlaxoSmithKline
- Kathryn Colby
- University of Chicago Medical Center
- DOI
- https://doi.org/10.1007/s40123-020-00289-z
- Journal volume & issue
-
Vol. 9,
no. 4
pp. 913 – 915
Abstract
The authors of the above mentioned article would like to highlight the following corrections, based upon recent changes to the FDA label and guidance on the use of belamaf
